

December 5, 2018

Ontario Securities Commission

To whom it may concern,

Re: Rapid Dose Therapeutics Inc. (the “Company”)

We refer to the non-offering prospectus of Acme Resources Corp, relating to the listing of common shares to comply with Policy 2 – Qualifications for Listing of the Canadian Securities Exchange, which incorporates by reference, our audit opinion Rapid Dose Therapeutics Inc. (the “Company”) dated December 5, 2018.

We consent to being named and to the use, by reference, in the above-mentioned disclosure document, of our report dated December 5, 2018 to the shareholders of the Company on the financial position of the Company as at February 28, 2018 and the statements of loss comprehensive loss, changes in equity and cash flows from the date of incorporation of May 3, 2017 to February 28, 2018, and a summary of significant accounting policies and other explanatory information.

We report that we have read the disclosure document and all information therein and have no reason to believe that there are any misrepresentations in the information contained therein that are derived from the financial statement upon which we have reported or that are within our knowledge as a result of our audit of such financial statements. We have complied with Canadian generally accepted standards for an auditor’s consent to the use of a report of the auditor included in an offering documents, which does not constitute an audit or review of the disclosure document as these terms are described in the CPA Canada Handbook – Assurance.

Yours truly,



Chartered Professional Accountants
Licensed Public Accountants